Symbols / RPTX
RPTX Chart
About
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada. As of January 28, 2026, Repare Therapeutics Inc. operates as a subsidiary of Xenotherapeutics Inc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 114.24M |
| Enterprise Value | 1.65M | Income | -72.20M | Sales | 11.87M |
| Book/sh | 2.68 | Cash/sh | 2.62 | Dividend Yield | — |
| Payout | 0.00% | Employees | 129 | IPO | Jun 19, 2020 |
| P/E | — | Forward P/E | -0.89 | PEG | — |
| P/S | 9.62 | P/B | 0.99 | P/C | — |
| EV/EBITDA | -0.02 | EV/Sales | 0.14 | Quick Ratio | 10.40 |
| Current Ratio | 10.71 | Debt/Eq | 0.30 | LT Debt/Eq | — |
| EPS (ttm) | -1.70 | EPS next Y | -2.97 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 16:00 | ROA | -29.72% |
| ROE | -49.78% | ROIC | — | Gross Margin | 4.03% |
| Oper. Margin | -3.70% | Profit Margin | 0.00% | Shs Outstand | 43.11M |
| Shs Float | 22.86M | Short Float | 1.62% | Short Ratio | 0.31 |
| Short Interest | — | 52W High | 2.66 | 52W Low | 0.89 |
| Beta | 0.96 | Avg Volume | 1.21M | Volume | 1.17M |
| Target Price | $3.00 | Recom | None | Prev Close | $2.65 |
| Price | $2.65 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.00
Mean price target
2. Current target
$2.65
Latest analyst target
3. DCF / Fair value
$-17.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.65
Low
$3.00
High
$3.00
Mean
$3.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-27 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-07 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-12-13 | down | LifeSci Capital | Outperform → Market Perform | — |
| 2024-12-13 | main | Stifel | Buy → Buy | $4 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-09-23 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-09-04 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-30 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-03-08 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-02-21 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-02-14 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-11-20 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2023-10-16 | main | Piper Sandler | Overweight → Overweight | $25 |
| 2023-09-25 | main | Stifel | Buy → Buy | $17 |
| 2023-08-17 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2023-06-09 | up | Stifel | Hold → Buy | $16 |
| 2023-06-09 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2023-04-27 | reit | HC Wainwright & Co. | — → Buy | $25 |
- RPTX - Repare Therapeutics Inc. Latest Stock News & Market Updates - Stock Titan Fri, 16 Jan 2026 08
- Repare Therapeutics Inc. (RPTX) Reports Break-Even Earnings for Q3 - Yahoo Finance Fri, 14 Nov 2025 08
- RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug - Stocktwits hu, 25 Dec 2025 08
- Repare Therapeutics stock soars after acquisition deal with XenoTherapeutics - Investing.com Fri, 14 Nov 2025 08
- Repare (NASDAQ: RPTX) enters definitive deal to be acquired; holders to get $1.82 plus one CVR - Stock Titan Fri, 14 Nov 2025 08
- Gilead to buy Repare Thera’s cancer candidate for up to $30M - Seeking Alpha Wed, 24 Dec 2025 08
- Repare Therapeutics Announces Acquisition by XenoTherapeutics - TipRanks Mon, 17 Nov 2025 08
- Repare Therapeutics (RPTX) to Be Acquired by XenoTherapeutics - GuruFocus Fri, 14 Nov 2025 08
- Repare Therapeutics (RPTX) Just Exploded: Is This Tiny Cancer Stock Your Next Huge Win or a Total Tr - AD HOC NEWS Sun, 01 Feb 2026 08
- Repare Therapeutics (RPTX) on Acquisition Path: Explained - timothysykes.com Mon, 17 Nov 2025 08
- Is Repare Therapeutics (NASDAQ:RPTX) In A Good Position To Deliver On Growth Plans? - simplywall.st ue, 29 Apr 2025 07
- Can RPTX continue delivering strong returns - Trade Entry Report & Smart Allocation Stock Reports - mfd.ru hu, 12 Feb 2026 15
- RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug - Asianet Newsable Wed, 24 Dec 2025 08
- Cathie Wood Snags Robinhood Stock (HOOD) and GitLab (GTLB) as Markets Slide - The Globe and Mail Fri, 04 Apr 2025 07
- Repare Therapeutics to be Acquired by XenoTherapeutics in Strategic Move - TipRanks Fri, 14 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4100 | — | — | Stock Award(Grant) at price 0.00 per share. | ALVES SANDRA ISABELLE BARROS | Officer | — | 2025-04-02 00:00:00 | D |
| 1 | 21179 | 24144 | — | Sale at price 1.14 per share. | SEGAL LLOYD MITCHELL | Chief Executive Officer | — | 2025-03-12 00:00:00 | D |
| 2 | 5611 | 6397 | — | Sale at price 1.14 per share. | ZINDA MICHAEL | Officer | — | 2025-03-12 00:00:00 | D |
| 3 | 6884 | 7848 | — | Sale at price 1.14 per share. | FORTE STEVE | Chief Financial Officer | — | 2025-03-12 00:00:00 | D |
| 4 | 3596 | 4099 | — | Sale at price 1.14 per share. | KOEHLER MARIA | Officer | — | 2025-03-12 00:00:00 | D |
| 5 | 40000 | — | — | Stock Award(Grant) at price 0.00 per share. | SEGAL LLOYD MITCHELL | Chief Executive Officer | — | 2025-03-04 00:00:00 | D |
| 6 | 14000 | — | — | Stock Award(Grant) at price 0.00 per share. | ZINDA MICHAEL | Officer | — | 2025-03-04 00:00:00 | D |
| 7 | 14000 | — | — | Stock Award(Grant) at price 0.00 per share. | FORTE STEVE | Chief Financial Officer | — | 2025-03-04 00:00:00 | D |
| 8 | 5141 | 23776 | — | Sale at price 4.62 - 4.63 per share. | SEGAL LLOYD MITCHELL | Chief Executive Officer | — | 2024-04-01 00:00:00 | I |
| 9 | 860 | 3999 | — | Sale at price 4.64 - 4.66 per share. | ZINDA MICHAEL | Officer | — | 2024-04-01 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -207.15K | -15.46K | 80.73K | -2.23K |
| TaxRateForCalcs | 0.15 | 0.09 | 0.26 | 0.02 |
| NormalizedEBITDA | -88.84M | -114.10M | -18.13M | -107.05M |
| TotalUnusualItems | -1.38M | -170.00K | 308.00K | -144.00K |
| TotalUnusualItemsExcludingGoodwill | -1.38M | -170.00K | 308.00K | -144.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -84.69M | -93.80M | -29.05M | -106.91M |
| ReconciledDepreciation | 1.92M | 1.95M | 1.98M | 1.47M |
| EBITDA | -90.22M | -114.27M | -17.82M | -107.19M |
| EBIT | -92.14M | -116.22M | -19.80M | -108.66M |
| NetInterestIncome | 10.39M | 13.33M | 5.63M | 259.00K |
| InterestIncome | 10.39M | 13.33M | 5.63M | 259.00K |
| NormalizedIncome | -83.52M | -93.64M | -29.27M | -106.77M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -84.69M | -93.80M | -29.05M | -106.91M |
| TotalExpenses | 145.62M | 167.36M | 151.63M | 116.26M |
| TotalOperatingIncomeAsReported | -93.52M | -116.22M | -19.80M | -108.66M |
| DilutedAverageShares | 42.41M | 42.09M | 41.92M | 37.82M |
| BasicAverageShares | 42.41M | 42.09M | 41.92M | 37.82M |
| DilutedEPS | -2.00 | -2.23 | -0.69 | -2.83 |
| BasicEPS | -2.00 | -2.23 | -0.69 | -2.83 |
| DilutedNIAvailtoComStockholders | -84.69M | -93.80M | -29.05M | -106.91M |
| NetIncomeCommonStockholders | -84.69M | -93.80M | -29.05M | -106.91M |
| NetIncome | -84.69M | -93.80M | -29.05M | -106.91M |
| NetIncomeIncludingNoncontrollingInterests | -84.69M | -93.80M | -29.05M | -106.91M |
| NetIncomeContinuousOperations | -84.69M | -93.80M | -29.05M | -106.91M |
| TaxProvision | 1.44M | -9.38M | 15.15M | -1.68M |
| PretaxIncome | -83.25M | -103.18M | -13.90M | -108.59M |
| OtherIncomeExpense | -1.50M | -289.00K | 265.00K | -185.00K |
| OtherNonOperatingIncomeExpenses | -115.00K | -119.00K | -43.00K | -41.00K |
| SpecialIncomeCharges | -1.38M | 0.00 | ||
| RestructuringAndMergernAcquisition | 1.38M | 0.00 | ||
| GainOnSaleOfSecurity | -2.00K | -170.00K | 308.00K | -144.00K |
| NetNonOperatingInterestIncomeExpense | 10.39M | 13.33M | 5.63M | 259.00K |
| InterestIncomeNonOperating | 10.39M | 13.33M | 5.63M | 259.00K |
| OperatingIncome | -92.14M | -116.22M | -19.80M | -108.66M |
| OperatingExpense | 145.62M | 167.36M | 151.63M | 116.26M |
| ResearchAndDevelopment | 115.94M | 133.59M | 119.07M | 90.05M |
| SellingGeneralAndAdministration | 29.68M | 33.76M | 32.56M | 26.21M |
| GeneralAndAdministrativeExpense | 29.68M | 33.76M | 32.56M | 26.21M |
| OtherGandA | 29.68M | 33.76M | 32.56M | 26.21M |
| TotalRevenue | 53.48M | 51.13M | 131.83M | 7.60M |
| OperatingRevenue | 53.48M | 51.13M | 131.83M | 7.60M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 42.51M | 42.18M | 42.04M | 41.85M |
| ShareIssued | 42.51M | 42.18M | 42.04M | 41.85M |
| TotalDebt | 1.93M | 3.41M | 5.43M | 7.31M |
| TangibleBookValue | 151.13M | 212.08M | 279.52M | 288.42M |
| InvestedCapital | 151.13M | 212.08M | 279.52M | 288.42M |
| WorkingCapital | 145.86M | 204.61M | 275.36M | 316.32M |
| NetTangibleAssets | 151.13M | 212.08M | 279.52M | 288.42M |
| CapitalLeaseObligations | 1.93M | 3.41M | 5.43M | 7.31M |
| CommonStockEquity | 151.13M | 212.08M | 279.52M | 288.42M |
| TotalCapitalization | 151.13M | 212.08M | 279.52M | 288.42M |
| TotalEquityGrossMinorityInterest | 151.13M | 212.08M | 279.52M | 288.42M |
| StockholdersEquity | 151.13M | 212.08M | 279.52M | 288.42M |
| OtherEquityInterest | 10.00K | |||
| GainsLossesNotAffectingRetainedEarnings | 54.00K | 28.00K | -428.00K | 0.00 |
| OtherEquityAdjustments | 54.00K | 28.00K | -428.00K | |
| RetainedEarnings | -417.80M | -333.11M | -239.31M | -210.27M |
| AdditionalPaidInCapital | 82.19M | 61.81M | 37.23M | 17.99M |
| CapitalStock | 486.67M | 483.35M | 482.03M | 480.70M |
| CommonStock | 486.67M | 483.35M | 482.03M | 480.70M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 25.38M | 41.82M | 84.56M | 80.29M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 88.00K | 2.74M | 5.94M | 45.20M |
| NonCurrentDeferredLiabilities | 0.00 | 1.73M | 2.68M | 39.61M |
| NonCurrentDeferredRevenue | 0.00 | 1.73M | 2.68M | 39.61M |
| LongTermDebtAndCapitalLeaseObligation | 88.00K | 1.01M | 3.26M | 5.59M |
| LongTermCapitalLeaseObligation | 88.00K | 1.01M | 3.26M | 5.59M |
| CurrentLiabilities | 25.29M | 39.08M | 78.62M | 35.09M |
| OtherCurrentLiabilities | 166.00K | 194.00K | 271.00K | 377.00K |
| CurrentDeferredLiabilities | 0.00 | 10.22M | 53.10M | 11.92M |
| CurrentDeferredRevenue | 0.00 | 10.22M | 53.10M | 11.92M |
| CurrentDebtAndCapitalLeaseObligation | 1.84M | 2.40M | 2.17M | 1.72M |
| CurrentCapitalLeaseObligation | 1.84M | 2.40M | 2.17M | 1.72M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.62M | 6.98M | 5.62M | 4.87M |
| PayablesAndAccruedExpenses | 17.66M | 19.28M | 17.46M | 16.20M |
| CurrentAccruedExpenses | 14.04M | 16.88M | 15.76M | 13.38M |
| Payables | 3.62M | 2.40M | 1.70M | 2.83M |
| TotalTaxPayable | 0.00 | 1.24M | 523.00K | |
| IncomeTaxPayable | 0.00 | 1.24M | 523.00K | |
| AccountsPayable | 3.62M | 2.40M | 461.00K | 2.30M |
| TotalAssets | 176.51M | 253.90M | 364.07M | 368.71M |
| TotalNonCurrentAssets | 5.36M | 10.21M | 10.10M | 17.30M |
| OtherNonCurrentAssets | 179.00K | 396.00K | 497.00K | 586.00K |
| NonCurrentDeferredAssets | 0.00 | 3.62M | ||
| NonCurrentDeferredTaxesAssets | 0.00 | 3.62M | ||
| NonCurrentAccountsReceivable | 960.00K | 2.28M | ||
| NetPPE | 4.22M | 7.54M | 9.60M | 13.10M |
| AccumulatedDepreciation | -9.20M | -7.30M | -5.35M | -3.38M |
| GrossPPE | 13.42M | 14.85M | 14.95M | 16.47M |
| Leases | 2.55M | 2.55M | 2.52M | 2.46M |
| OtherProperties | 9.89M | 11.31M | 11.45M | 13.03M |
| MachineryFurnitureEquipment | 987.00K | 987.00K | 987.00K | 978.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 171.15M | 243.69M | 353.98M | 351.41M |
| OtherCurrentAssets | 5.71M | 6.31M | ||
| PrepaidAssets | 6.01M | 4.75M | 5.71M | 6.31M |
| Receivables | 12.35M | 15.31M | 4.32M | 3.23M |
| OtherReceivables | 1.75M | 4.50M | 4.32M | 654.00K |
| TaxesReceivable | 10.60M | 10.81M | 0.00 | 2.58M |
| CashCashEquivalentsAndShortTermInvestments | 152.79M | 223.63M | 343.94M | 341.87M |
| OtherShortTermInvestments | 68.07M | 112.36M | 184.42M | 7.44M |
| CashAndCashEquivalents | 84.72M | 111.27M | 159.52M | 334.43M |
| CashEquivalents | 40.95M | 66.81M | 42.99M | 2.54M |
| CashFinancial | 43.76M | 44.46M | 116.53M | 331.89M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -76.44M | -129.10M | -280.00K | -87.49M |
| IssuanceOfCapitalStock | 0.00 | 94.29M | ||
| CapitalExpenditure | -1.94M | -602.00K | -1.69M | |
| IncomeTaxPaidSupplementalData | 139.00K | 4.95M | 10.81M | 25.00K |
| EndCashPosition | 84.72M | 111.27M | 159.52M | 334.43M |
| BeginningCashPosition | 111.27M | 159.52M | 334.43M | 326.40M |
| EffectOfExchangeRateChanges | -116.00K | 22.00K | -330.00K | -54.00K |
| ChangesInCash | -26.43M | -48.27M | -174.58M | 8.09M |
| FinancingCashFlow | 542.00K | 842.00K | 880.00K | 95.56M |
| CashFlowFromContinuingFinancingActivities | 542.00K | 842.00K | 880.00K | 95.56M |
| ProceedsFromStockOptionExercised | 542.00K | 842.00K | 880.00K | 1.27M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 0.00 | 94.29M | ||
| CommonStockIssuance | 0.00 | 94.29M | ||
| InvestingCashFlow | 49.47M | 78.04M | -175.78M | -1.68M |
| CashFlowFromContinuingInvestingActivities | 49.47M | 78.04M | -175.78M | -1.68M |
| NetInvestmentPurchaseAndSale | 49.47M | 79.98M | -175.18M | -26.00K |
| SaleOfInvestment | 182.82M | 259.00M | 81.40M | 7.45M |
| PurchaseOfInvestment | -133.35M | -179.02M | -256.58M | -7.48M |
| NetPPEPurchaseAndSale | 0.00 | -1.94M | -602.00K | -1.65M |
| SaleOfPPE | 0.00 | 40.00K | ||
| PurchaseOfPPE | 0.00 | -1.94M | -602.00K | -1.69M |
| OperatingCashFlow | -76.44M | -127.16M | 322.00K | -85.80M |
| CashFlowFromContinuingOperatingActivities | -76.44M | -127.16M | 322.00K | -85.80M |
| ChangeInWorkingCapital | -14.06M | -55.18M | 8.03M | 4.79M |
| ChangeInOtherWorkingCapital | -10.42M | -58.16M | 7.87M | -8.68M |
| ChangeInOtherCurrentLiabilities | -2.31M | -2.22M | -1.53M | -1.02M |
| ChangeInOtherCurrentAssets | 217.00K | 101.00K | 89.00K | -298.00K |
| ChangeInPayablesAndAccruedExpense | -2.99M | 4.35M | 2.39M | 11.82M |
| ChangeInAccruedExpense | -4.22M | 2.41M | 3.02M | 11.17M |
| ChangeInPayable | 1.23M | 1.93M | -631.00K | 657.00K |
| ChangeInAccountPayable | 1.23M | 1.93M | -1.35M | 152.00K |
| ChangeInTaxPayable | -14.33M | 717.00K | 505.00K | |
| ChangeInIncomeTaxPayable | -14.33M | 717.00K | 505.00K | |
| ChangeInPrepaidAssets | -1.26M | 969.00K | 593.00K | -32.00K |
| ChangeInReceivables | 2.72M | -216.00K | -1.39M | 3.00M |
| ChangesInAccountReceivables | -1.52M | 0.00 | ||
| OtherNonCashItems | 2.36M | 2.19M | 2.21M | 1.87M |
| StockBasedCompensation | 23.17M | 25.06M | 19.69M | 12.83M |
| AmortizationOfSecurities | -5.16M | -7.46M | -2.23M | 113.00K |
| DepreciationAmortizationDepletion | 1.92M | 1.95M | 1.98M | 1.47M |
| DepreciationAndAmortization | 1.92M | 1.95M | 1.98M | 1.47M |
| Depreciation | 1.92M | 1.95M | 1.98M | 1.47M |
| OperatingGainsLosses | 8.00K | 78.00K | -298.00K | 36.00K |
| NetForeignCurrencyExchangeGainLoss | 8.00K | 78.00K | -298.00K | 12.00K |
| GainLossOnSaleOfPPE | 0.00 | 24.00K | ||
| NetIncomeFromContinuingOperations | -84.69M | -93.80M | -29.05M | -106.91M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for RPTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|